ArticleThe American journal of pathology2011
Targeting ST2L potentiates CpG-mediated therapeutic effects in a chronic fungal asthma model.
Article in The American journal of pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- PANoptosis opens new treatment options for allergic bronchopulmonary aspergillosis.The journal of allergy and clinical immunology. Global · 2024Article
- Interplay of IL-33 and IL-35 Modulates Th2/Th17 Responses in Cigarette Smoke Exposure HDM-Induced Asthma.Inflammation · 2024Article
- Hematopoietic 12/15-lipoxygenase activity negatively contributes to fungal-associated allergic asthma.American journal of physiology. Lung cellular and molecular physiology · 2023Article
- Knowledge mapping and research trends of IL-33 from 2004 to 2022: a bibliometric analysis.Frontiers in immunology · 2023Article
- Increased expression of IL1-RL1 is associated with type 2 and type 1 immune pathways in asthma.BMC immunology · 2022Article
- Chitinase 3-like-1 protects airway function despite promoting type 2 inflammation during fungal-associated allergic airway inflammation.American journal of physiology. Lung cellular and molecular physiology · 2021Article
- Article
- Role for IL-1 Family Cytokines in Fungal Infections.Frontiers in microbiology · 2021Review
- The common γ-chain cytokine IL-7 promotes immunopathogenesis during fungal asthma.Mucosal immunology · 2018Article
- IL-33 Signaling Regulates Innate IL-17A and IL-22 Production via Suppression of Prostaglandin EJournal of immunology (Baltimore, Md. : 1950) · 2017Article
- IL-33: biological properties, functions, and roles in airway disease.Immunological reviews · 2017Review
- Prospects to translate the biology of IL-33 and ST2 during organ transplantation into therapeutics to treat graft-versus-host disease.Annals of translational medicine · 2016Article
- Distinct Tlr4-expressing cell compartments control neutrophilic and eosinophilic airway inflammation.Mucosal immunology · 2015Article
- Crucial and diverse role of the interleukin-33/ST2 axis in infectious diseases.Infection and immunity · 2015Review
- Invariant natural killer T cells recognize a fungal glycosphingolipid that can induce airway hyperreactivity.Nature medicine · 2013Article
- Review
- Adenovirus-mediated delivery of soluble ST2 attenuates ovalbumin-induced allergic asthma in mice.Clinical and experimental immunology · 2012Article
- The β-glucan receptor dectin-1 promotes lung immunopathology during fungal allergy via IL-22.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Dynamic role of epithelium-derived cytokines in asthma.Clinical immunology (Orlando, Fla.) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-33 and its soluble receptor and cell-associated receptor (ST2L) are all increased in clinical and experimental asthma. The present study addressed the hypothesis that ST2L impairs the therapeutic effects of CpG in a fungal model of asthma. C57BL/6 mice were sensitized to Aspergillus fumigatus and challenged via i.t. instillation with live A. fumigatus conidia. Mice were treated with IgG alone, anti-ST2L monoclonal antibody (mAb) alone, CpG alone, IgG plus CpG, or anti-ST2L mAb plus CpG every other day from day 14 to day 28 and investigated on day 28 after conidia. Lung ST2L and toll-like receptor 9 protein expression levels concomitantly increased in a time-dependent manner during fungal asthma. Therapeutic blockade of ST2L with an mAb attenuated key pathological features of this model. At subtherapeutic doses, neither anti-ST2L mAb nor CpG alone affected fungal asthma severity. However, airway hyperresponsiveness, mucus cell metaplasia, peribronchial fibrosis, and fungus retention were markedly reduced in asthmatic mice treated with the combination of both. Whole lung CXCL9 levels were significantly elevated in the combination group but not in the controls. Furthermore, in asthmatic mice treated with the combination therapy, dendritic cells generated significantly greater IL-12p70 with CpG in vitro compared with control dendritic cells. The combination of anti-ST2L mAb with CpG significantly attenuated experimental asthma, suggesting that targeting ST2L might enhance the therapeutic efficacy of CpG during allergic inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.